By Louis Blankemeier
In October 2024, my co-founders and I embarked on a mission to translate our Ph.D. research into tangible healthcare solutions. We developed AI models capable of interpreting medical images such as X-rays and CT scans across thousands of potential diagnoses, creating comprehensive radiology reports that mirror radiologists’ clinical reasoning. This represented a major leap at a time when AI in radiology only flagged a few specific conditions.
Less than a year later, we faced a critical decision: continue raising venture capital and advance independently or accept an acquisition from Radiology Partners, the largest radiology practice worldwide. Contrary to the tech norm emphasizing independence, we chose collaboration to significantly boost our chances of transforming healthcare access.
Clinical AI faces complex regulatory hurdles, long sales cycles, and challenging market dynamics that favor well-established players. Joining forces with a major industry player offered resources, extensive data, and clinical integration required to develop reliable, scalable models. Research-scale successes do not guarantee clinical readiness; real-world radiology demands massive, diverse datasets and continuous performance monitoring to handle complex, high-stakes cases.
Moreover, sustainable success in healthcare AI hinges on rigorous evidence from large-scale implementation across diverse populations and environments, not small pilots. Partnering with Radiology Partners provided the infrastructure and credibility essential for trust and adoption, accelerating our mission to expand access to high-quality healthcare worldwide.
Louis Blankemeier is CEO and co-founder of Cognita, part of Radiology Partners. His work bridges AI research and clinical application, driven to improve healthcare accessibility through technology.
